- Home
- ERNA vs AIOS Comparison
ERNA vs AIOS Comparison
Compare ERNA & AIOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERNA | AIOS |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 4.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ERNA | AIOS |
|---|---|---|
| Price | $7.66 | $19.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 488.7K |
| Earning Date | 05-07-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $582,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.39 |
| 52 Week High | $7.70 | $33.87 |
Technical Indicators
Market Signals| Indicator | ERNA | AIOS |
|---|---|---|
| Relative Strength Index (RSI) | 98.80 | 75.48 |
| Support Level | $0.23 | $0.48 |
| Resistance Level | N/A | $33.87 |
| Average True Range (ATR) | 0.44 | 4.42 |
| MACD | 0.79 | 1.74 |
| Stochastic Oscillator | 97.24 | 57.97 |
Price Performance
Historical ComparisonAbout ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.